FSD Pharma Closes CAD$16.4 Million Sale of Non-core Assets
FSD Pharma (HUGE) sold its assets related to cannabis processing to focus on biotech. The C$16.4M in proceeds give the company enough capital to support operations through 2025.
PharmAla Biotech Expands MDMA Distribution with CCrest Labs
PharmAla Biotech Expands MDMA Distribution with CCrest Labs
PharmAla Biotech (MDMA) signed a distribution agreement with CCrest Laboratories, making its MDMA available to both international and domestic customers.
Announces Singular Focus on Drug Development Prompting a Strategic Review of its Clinics and Other Care Delivery Assets
Wesana Announces Singular Focus on Drug Development Prompting a Strategic Review of its Clinics and Other Care Delivery Assets
Wesana Health (WESA) is considering selling all assets related to client care (like its network of ketamine clinics and mental health software) to focus solely on drug development.
Optimi opens Canada’s largest psilocybin cultivation facility
Optimi Health Opens Canada’s Largest GMP-Grade Licensed Psilocybin Cultivation Facility
Optimi Health (OPTI) opened the largest psilocybin cultivation facility in Canada and received approval to increase its production limit to 5000kg of dried psilocybin mushrooms. An in-person and virtual tour will be showcased on May 27.
PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update
PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update
PharmaTher (PHRM) announced Q3 financial results including C$10.1M in cash. The company is focused on treating rare disorders with ketamine and creating novel methods of administering psychedelics.
Nirvana Announces First Production of Psilocybin and Psilocin
Nirvana Announces First Production of Psilocybin and Psilocin
Nirvana Life Sciences (NIRV), a recently listed company focused on opioid addiction and chronic pain, received its first batch of psilocybin and psilocin for R&D projects.
Public library of magic mushroom DNA
Magic Mushrooms Have Over 80 Different Species—And Their DNA Is Now Available Online
Medicinal Genomics Corp. launched Psilocydia, a public database containing genetic information of 80+ strains of psilocybin mushrooms. Psilocydia will help cultivators discover genetic traits, select genes of interest, and distinguish beneficial mushrooms from poisonous ones.
Psychedelic startup makes a deal with Big Pharma
Terran Biosciences announces licensing deal with Sanofi for two late-stage CNS pipeline assets
Terran Biosciences, a private psychedelic startup, announced a licensing deal with the French Big Pharma company Sanofi (SNY). Terran will license two of Sanofi’s pipeline assets that target central nervous system (CNS) disorders. The assets have generated more than 100 clinical studies involving 15,000 subjects on a variety of CNS disorders.
Nue Life to expand to 20+ new states
Nue Life Health raises $23M Series A Led by Obvious Ventures for psychedelics platform
Nue Life raised $23M in equity financing to support the expansion of its innovative at-home ketamine services into more than 20 new states this year.
Psyence and Filament Health Enter Into Exclusive Licensing Agreements For Natural Psilocybin Products
Psyence and Filament Health Enter Into Exclusive Licensing Agreements For Natural Psilocybin Products
Filament Health (FH) granted Psyence Group (PSYG) an exclusive license to use its natural psilocybin formulation in an upcoming palliative care trial in the UK. Filament recently received a patent for its technology for extracting and standardizing natural psilocybin.